TY - JOUR
T1 - Interaction of histamine and calcitonin gene-related peptide in the formalin-induced pain perception in rats
AU - Mobarakeh, Jalal Izadi
AU - Torkaman-Boutorabi, Anahita
AU - Rahimi, Amir Abbas
AU - Ghasri, Shahrooz
AU - Nezhad, Reza Mohammad Ali
AU - Hamzely, Arash
AU - Sima, Baharak Khoshkholgh
AU - Takahashi, Kazuhiro
AU - Nunoki, Kazuo
AU - Yanai, Kazuhiko
PY - 2011
Y1 - 2011
N2 - Histamine and calcitonin gene-related peptide (CGRP) contribute to the pain perception. The aim of the present study is to clarify the interaction of histamine and CGRP in the perception of inflammatory pain. The effects of a histamine H1 receptor antagonist (pyrilamine, i.p.), an H2 receptor antagonist (ranitidine, i.p.) and a CGRP antagonist (CGRP 8-37, i.t.) on the formalin-induced pain was studied in rats. Pyrilamine and ranitidine produced a dose-dependent antinociceptive response in the first and the second phases of the formalin test. A single administration of pyrilamine (1 mg/kg, i.p.), ranitidine (10 mg/kg, i.p.) or CGRP 8-37 (10 μg/μL, i.t.) had no significant effects on the pain perception in the second phase. A combination of CGRP 8-37 and pyrilamine or ranitidine at these sub-effective doses, however, showed nociceptive response in the second phase. Moreover, a histamine (i.t.)-induced hyperalgesia was completely prevented by treatment with GGRP 8-37 at this dose. Our findings have raised the possibility that the CGRP system has interaction with histamine in the perception of inflammatory pain.
AB - Histamine and calcitonin gene-related peptide (CGRP) contribute to the pain perception. The aim of the present study is to clarify the interaction of histamine and CGRP in the perception of inflammatory pain. The effects of a histamine H1 receptor antagonist (pyrilamine, i.p.), an H2 receptor antagonist (ranitidine, i.p.) and a CGRP antagonist (CGRP 8-37, i.t.) on the formalin-induced pain was studied in rats. Pyrilamine and ranitidine produced a dose-dependent antinociceptive response in the first and the second phases of the formalin test. A single administration of pyrilamine (1 mg/kg, i.p.), ranitidine (10 mg/kg, i.p.) or CGRP 8-37 (10 μg/μL, i.t.) had no significant effects on the pain perception in the second phase. A combination of CGRP 8-37 and pyrilamine or ranitidine at these sub-effective doses, however, showed nociceptive response in the second phase. Moreover, a histamine (i.t.)-induced hyperalgesia was completely prevented by treatment with GGRP 8-37 at this dose. Our findings have raised the possibility that the CGRP system has interaction with histamine in the perception of inflammatory pain.
UR - http://www.scopus.com/inward/record.url?scp=79959825336&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79959825336&partnerID=8YFLogxK
U2 - 10.2220/biomedres.32.195
DO - 10.2220/biomedres.32.195
M3 - Article
C2 - 21673449
AN - SCOPUS:79959825336
SN - 0388-6107
VL - 32
SP - 195
EP - 201
JO - Biomedical Research (Japan)
JF - Biomedical Research (Japan)
IS - 3
ER -